Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.

Liu Q, Davit BM, Cherstniakova SA, Dandamudi S, Walters JF, Lee CH, Raines KW, Ren K, Williamson LN, Conner DP.

AAPS J. 2012 Mar;14(1):19-22. doi: 10.1208/s12248-011-9312-7. Epub 2011 Dec 1.

2.

High performance liquid chromatographic measurement of iothalamate in human serum and urine for evaluation of glomerular filtration rate.

Bi D, Leary KJ, Weitz JA, Cherstniakova SA, Reil MA, Roy MJ, Cantilena LR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):95-9. Epub 2007 Jun 6.

PMID:
17599846
3.

Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during phase 1 clinical trials.

Cantilena LR, Cherstniakova SA, Saviolakis G, Kahn R, Elkashef A, Rose L, Vocci F.

Contemp Clin Trials. 2007 Nov;28(6):695-704. Epub 2007 Mar 19.

PMID:
17544338
4.

Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety.

Roy MJ, Kraus PL, Seegers CA, Young SY, Kamens DR, Law WA, Cherstniakova SA, Chang DN, Cooper JA, Sato PA, Matulich W, Krantz DS, Cantilena LR, Deuster PA.

Mayo Clin Proc. 2006 Oct;81(10):1303-10.

PMID:
17036555
5.
6.

Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.

Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR.

Drug Metab Dispos. 2001 Sep;29(9):1216-20.

PMID:
11502731

Supplemental Content

Loading ...
Support Center